DiaSorin completed EUR 250 million buyback. DiaSorin stock gains 1.52 percent

Published on 10/09/2026 at 14:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half 2026 revenue was EUR 602 million, flat at constant rates. DiaSorin stock costs EUR 77.01 on October 9, 2026 after EUR 75.86.

Key points in brief

DiaSorin completed its EUR 250.00 million buyback program on October 7, 2026.
The program covered 3,790,952 shares, equal to 6.78 percent of share capital.
First-half 2026 revenue reached EUR 602.00 million and was flat at constant exchange rates.
DiaSorin stock was at EUR 77.01 at Lang & Schwarz on October 9, 2026, up 1.52 percent versus EUR 75.86.

Techniker im Reinraum bedienen automatisierte Diagnostikgeräte in modernem Biotech-Labor — Modernes Diagnostiklabor von DiaSorin S.p.A., ISIN IT0003497168, zeigt präzise Biotech-Produktion und klinische Fertigung, Illustration mit AI erstellt.

DiaSorin completed its EUR 250.00 million buyback program on October 7, 2026, while DiaSorin stock was trading at EUR 77.01 at Lang & Schwarz on October 9, 2026, up 1.52 percent versus the EUR 75.86 prior close. According to DiaSorin, the purchases reached the program ceiling and the shares are intended for cancellation.

Three dates define the story

On July 31, 2026, DiaSorin reported first-half revenue of EUR 602 million and confirmed its full-year outlook. On October 2, 2026, the company appointed Margherita Sacerdoti as Investor Relations and ESG Senior Director, according to DiaSorin. On October 7, 2026, the company disclosed the completion of the EUR 250.00 million buyback, making the repurchase the latest dated corporate event.

What does the buyback change?

The final purchases covered 3,790,952 shares, equivalent to 6.78 percent of DiaSorin's share capital, for an aggregate consideration of EUR 249,999,986.67. The filing also states that treasury shares held by the company totaled 6,683,050, or 11.95 percent of share capital, as of October 5, 2026.

The transaction gives the market a precise measure of the capital return: the program used its full EUR 250.00 million authorization and bought no more than the planned 4.5 million shares. The cancellation objective means the repurchased shares are not simply being retained as treasury stock.

Revenue recovery meets margin pressure

In the second quarter of 2026, revenue grew 4.00 percent at constant exchange rates, after first-half revenue remained flat on the same basis. Yahoo Finance reported that adjusted EBITDA reached EUR 194 million in the first half of 2026, down 7.00 percent at constant exchange rates, while the adjusted EBITDA margin stood at 32.00 percent. Management confirmed full-year guidance for revenue growth of 5.00 percent to 6.00 percent and an adjusted EBITDA margin of 32.00 percent to 33.00 percent.

For investors, the contrast is clear: quarterly growth returned, but the first-half adjusted EBITDA decline and the buyback cash outflow keep capital allocation central to the story. DiaSorin's market capitalization was EUR 3.8 billion on October 9, 2026, and the EUR 77.01 Lang & Schwarz price stood 3.40 percent below the 52-week high of EUR 79.72.

Two dates remain on the calendar

DiaSorin's next reported results are listed for November 5, 2026, according to InvestPane. The company's financial calendar also lists November 12, 2026, for approval of third-quarter 2026 financial information, according to SoldiOnline.

Stock remains below its yearly high

At Lang & Schwarz, DiaSorin stock was trading at EUR 77.01 on October 9, 2026 at 2:00 p.m. CEST, up 1.52 percent versus the prior close of EUR 75.86. The 52-week range was EUR 52.34 to EUR 79.72, while market capitalization stood at EUR 3.8 billion on the same date. The further course of trading is shown by the continuously updated real-time quote of DiaSorin stock.